Holen Sie sich die Stockscreener-App
34.10
4.11%
-1.46
Handel nachbörslich:
34.15
0.05
+0.15%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt HROW?
Forum
Prognose
Aktiensplit
Harrow Inc Aktie (HROW) Neueste Nachrichten
Assessing Harrow (HROW) Valuation After Strong Revenue Growth And TRIESENCE Phase 3 Progress - simplywall.st
Why Harrow (HROW) Is Down 6.5% After Raising 2026 Guidance And Advancing TRIESENCE To Phase 3 - simplywall.st
Harrow Health at Leerink Global Healthcare Conference: Strategic Growth Focus - Investing.com
Harrow (HROW) Q4 2025 Earnings Call Transcript - AOL.com
HROW: Record growth and expanding ophthalmic portfolio drive optimism for future launches - TradingView
Harrow Inc (HROW) Q4 2025 Earnings Call Highlights: Record Revenue Growth and Strategic Expansions - Investing.com Canada
Harrow Health Projects Robust Growth After Strong 2025 - TipRanks
Is Harrow Inc. stock a top pick in earnings seasonTrade Performance Summary & Safe Entry Point Alerts - Naître et grandir
Harrow, Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:HROW) 2026-03-06 - Seeking Alpha
Has The Recent Slide In Harrow (HROW) Opened A Valuation Opportunity For Investors - simplywall.st
HC Wainwright Issues Negative Forecast for Harrow Earnings - MarketBeat
HROWHarrow Announces Cash-Pay Direct-to-Prescriber PharmaPack™ Kits - mx.advfn.com
Buy or Sell Harrow Stock? - Trefis
A Look At Harrow (HROW) Valuation After Mixed Q4 Results And 2026 Profitability Concerns - Yahoo Finance
A Look At Harrow (HROW) Valuation After Q4 2025 Earnings Miss And Raised 2026 Spending Plans - simplywall.st
HC Wainwright Has Pessimistic Outlook of Harrow Q3 Earnings - MarketBeat
Harrow (NASDAQ:HROW) Rating Lowered to "Strong Sell" at Zacks Research - MarketBeat
Harrow to Present at Leerink Partner’s 2026 Global Healthcare Conference - The Globe and Mail
H.C. Wainwright raises Harrow Health stock price target to $70 By Investing.com - Investing.com UK
Harrow stock stabilizes after major Tuesday drop - Nashville Post
Harrow Inc (HROW) Trading 4.78% Higher on Mar 4 - GuruFocus
Cantor Fitzgerald lowers Harrow Health stock price target to $91 - Investing.com
Cantor Fitzgerald Lowers Harrow (NASDAQ:HROW) Price Target to $91.00 - MarketBeat
These Analysts Revise Their Forecasts On Harrow Following Q4 Results - Benzinga
Harrow (HROW): Today's Analyst Rating and Price Target Update | - GuruFocus
Harrow (NASDAQ:HROW) Stock Price Expected to Rise, HC Wainwright Analyst Says - MarketBeat
Harrow Health, Inc. (NASDAQ:HROW) Q4 2025 Earnings Call Transcript - Insider Monkey
HROW: HC Wainwright & Co. Raises Price Target, Maintains Buy Rat - GuruFocus
Does Harrow’s (HROW) TRIESENCE Cataract Trial Redefine Its Dropless Eye Care Strategy? - simplywall.st
H.C. Wainwright raises Harrow Health stock price target to $70 - Investing.com
Harrow: The Post Earnings Drop Exposes The Cost Of Growth (Rating Downgrade) (NASDAQ:HROW) - Seeking Alpha
Harrow (HROW) -28%: 2026 Guidance Disappoints Market - Trefis
Would You Still Hold Harrow Stock If It Fell Another 30%? - Trefis
With Harrow Stock Sliding, Have You Assessed The Risk? - Trefis
Harrow 2026 slides: ophthalmic firm targets $357M revenue amid stock decline - Investing.com
Harrow (HROW) Projects Strong Growth with Expanding Ophthalmic P - GuruFocus
Opaleye-managed account sells Harrow (HROW) shares at $54.18 in Form 4 - Stock Titan
William Blair reiterates Harrow Health stock rating on ophthalmic growth - Investing.com
Harrow Shares Collapse, Another Opportunity? (NASDAQ:HROW) - Seeking Alpha
Notable Two Hundred Day Moving Average CrossHROW - Nasdaq
Why Is Eye-Disease-Focused Harrow Stock Falling Today? (UPDATED) - Benzinga
Harrow Q4 Earnings Call Highlights - MarketBeat
Yatsen Holding, Delta Air Lines, United Airlines And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Sahm
Harrow (NASDAQ:HROW) Shares Gap Down After Earnings Miss - MarketBeat
HROW: 2025 revenue grew 36% with strong momentum and 2026 guidance set at $350M–$365M - TradingView
HROW: Strong 2025 growth and expanded sales force set the stage for accelerated 2026 revenue - TradingView
Harrow Stock Falls 21% After FDA Clears IND Application For Phase 3 Trial Of TRIESENCE - Nasdaq
Harrow Health, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
MongoDB, Surgery Partners, Harrow And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Benzinga
HROW Gains FDA Approval for Phase 3 Trial of Triesence - GuruFocus
Harrow, Inc. (HROW) Stock Analysis: A 31.79% Upside in the Healthcare Sector Beckons Investors - DirectorsTalk Interviews
HROW: 2025 delivered robust revenue and EBITDA growth, with 2026 set for further expansion - TradingView
Eye drug TRIESENCE moves into Phase 3 test to ease cataract surgery recovery - Stock Titan
Harrow’s PharmaPack Aims To Reshape Post Cataract Care And Cash Pay Use - simplywall.st
Harrow Q4 Net Income Slips Despite 33% Revenue Growth; Issues FY26 Guidance; Stock Down - Nasdaq
Harrow Reports Substantial Q4 and Full-Year 2025 Revenue Growth - VisionMonday.com
Harrow Q4 2025 Earnings Report: Revenue $89.1M, Net Income $6.6MNews and StatisticsIndexBox - IndexBox - Market Intelligence Platform
Harrow Inc reports results for the quarter ended September 30Earnings Summary - TradingView
Harrow (HROW) Misses Q4 Earnings Estimates - Yahoo Finance
Harrow Health (HROW) Q4 Earnings Miss Despite Revenue Beat - GuruFocus
Harrow (HROW) Sets Ambitious Financial Targets for FY26 - GuruFocus
Harrow Reports Q4 Earnings - National Today
Harrow Announces Q4 and Full-Year 2025 Financial Results and 2026 Financial Guidance - Bitget
1.15%
3.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):